Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
Myriad Genetics (NASDAQ: MYGN) has announced a partnership with sports broadcaster Hannah Storm to promote their Breast Cancer Risk Assessment Program featuring the MyRisk® with RiskScore® Hereditary Cancer Test. Storm, who was diagnosed with stage zero Ductal Carcinoma in Situ (DCIS) in January 2024, will serve as an ambassador for the program.
The collaboration aims to raise awareness about the importance of knowing family cancer history and understanding associated risks. Storm's cancer was detected early through routine screening, highlighting the value of preventive measures. As a mother of three daughters, she emphasizes the significance of genetic testing for understanding hereditary risks.
According to Myriad Genetics, nearly half of women may not know their family health history. Storm will share content on her social media platforms about hereditary cancers and the importance of knowing both sides of family health history.
Myriad Genetics (NASDAQ: MYGN) ha annunciato una partnership con la sportiva Hannah Storm per promuovere il loro Programma di Valutazione del Rischio di Cancro al Seno, che include il test genetico MyRisk® con RiskScore®. Storm, diagnosticata con carcinoma duttale in situ (DCIS) in stadio zero nel gennaio 2024, fungerà da ambasciatrice per il programma.
La collaborazione mira ad aumentare la consapevolezza sull'importanza di conoscere la storia familiare del cancro e di comprendere i rischi associati. Il cancro di Storm è stato rilevato precocemente grazie a controlli di routine, evidenziando il valore delle misure preventive. In quanto madre di tre figlie, sottolinea l'importanza del test genetico per comprendere i rischi ereditari.
Secondo Myriad Genetics, quasi la metà delle donne potrebbe non conoscere la storia sanitaria della propria famiglia. Storm condividerà contenuti sulle sue piattaforme social riguardo ai tumori ereditari e all'importanza di conoscere la storia sanitaria di entrambe le famiglie.
Myriad Genetics (NASDAQ: MYGN) ha anunciado una asociación con la presentadora deportiva Hannah Storm para promover su Programa de Evaluación del Riesgo de Cáncer de Mama que incluye la prueba genética MyRisk® con RiskScore®. Storm, diagnosticada con carcinoma ductal in situ (DCIS) en etapa cero en enero de 2024, será embajadora del programa.
La colaboración tiene como objetivo aumentar la concienciación sobre la importancia de conocer la historia familiar de cáncer y comprender los riesgos asociados. El cáncer de Storm fue detectado de manera temprana a través de revisiones de rutina, lo que resalta el valor de las medidas preventivas. Como madre de tres hijas, enfatiza la importancia de las pruebas genéticas para entender los riesgos hereditarios.
Según Myriad Genetics, casi la mitad de las mujeres pueden no conocer su historia de salud familiar. Storm compartirá contenido en sus plataformas de redes sociales sobre cánceres hereditarios y la importancia de conocer la historia de salud de ambos lados de la familia.
Myriad Genetics (NASDAQ: MYGN)는 스포츠 방송인 Hannah Storm과 제휴하여 MyRisk®와 RiskScore® 유전 암 검사와 함께하는 유방암 위험 평가 프로그램을 홍보한다고 발표했습니다. Storm은 2024년 1월에 제로 단계의 관내 유관암(DCIS) 진단을 받았으며, 프로그램의 홍보 대사 역할을 맡게 됩니다.
이번 협력은 가족 암력의 중요성과 관련된 위험을 이해하는 것의 중요성에 대한 인식을 높이는 것을 목표로 합니다. Storm의 암은 정기 검진을 통해 조기에 발견되었으며, 이는 예방 조치의 가치를 강조합니다. 세 딸의 어머니로서, 유전적 위험을 이해하는 데 있어 유전 검사에 대한 중요성을 강조합니다.
Myriad Genetics에 따르면, 여성의 거의 절반이 자신의 가족 건강 기록을 알지 못할 수 있습니다. Storm은 그녀의 소셜 미디어 플랫폼에 유전 암에 관한 콘텐츠를 공유하고 가족 건강 기록에 대한 양측의 중요성을 알릴 것입니다.
Myriad Genetics (NASDAQ: MYGN) a annoncé un partenariat avec la présentatrice sportive Hannah Storm pour promouvoir leur Programme d'Évaluation du Risque de Cancer du Sein, qui comprend le test génétique MyRisk® avec RiskScore®. Storm, diagnostiquée avec un carcinome canalaire in situ (DCIS) au stade zéro en janvier 2024, sera ambassadrice du programme.
La collaboration vise à sensibiliser l'importance de connaître l'historique familial de cancer et de comprendre les risques associés. Le cancer de Storm a été détecté tôt grâce à un dépistage de routine, soulignant la valeur des mesures préventives. En tant que mère de trois filles, elle souligne l'importance des tests génétiques pour comprendre les risques héréditaires.
Selon Myriad Genetics, près de la moitié des femmes pourraient ne pas connaître leur historique de santé familial. Storm partagera du contenu sur ses plateformes de médias sociaux concernant les cancers héréditaires et l'importance de connaître l'historique de santé des deux côtés de la famille.
Myriad Genetics (NASDAQ: MYGN) hat eine Partnerschaft mit der Sportmoderatorin Hannah Storm angekündigt, um ihr Programm zur Beurteilung des Brustkrebserisikos zu fördern, das den MyRisk®-Test mit RiskScore® umfasst. Storm, die im Januar 2024 mit einem Duktalen Carcinoma in situ (DCIS) im Stadium 0 diagnostiziert wurde, wird als Botschafterin für das Programm fungieren.
Die Zusammenarbeit hat zum Ziel, das Bewusstsein für die Bedeutung der Kenntnis der familiären Krebsgeschichte und das Verständnis der damit verbundenen Risiken zu schärfen. Storrs Krebs wurde frühzeitig durch regelmäßige Untersuchungen erkannt, was den Wert präventiver Maßnahmen hervorhebt. Als Mutter von drei Töchtern betont sie die Bedeutung genetischer Tests zur Erfassung erblicher Risiken.
Laut Myriad Genetics wissen fast die Hälfte der Frauen möglicherweise nichts über ihre familiäre Gesundheitshistorie. Storm wird Inhalte auf ihren sozialen Medien über erbliche Krebserkrankungen und die Wichtigkeit der Kenntnis beider Seiten der Familiengeschichte teilen.
- Partnership with high-profile sports broadcaster increases visibility for MyRisk® cancer test
- Marketing campaign targets awareness of family health history, potentially driving test adoption
- None.
Insights
The partnership with Hannah Storm represents a marginal marketing initiative for Myriad Genetics. While Storm's personal battle with breast cancer and her platform as a sports broadcaster provide authenticity, the impact on MYGN's financial performance is likely to be minimal. Similar celebrity partnerships in the healthcare sector typically generate temporary awareness spikes but rarely translate to substantial revenue growth.
The timing aligns with increased public focus on preventive healthcare, but the campaign's effectiveness in driving MyRisk® test adoption faces several challenges: insurance coverage limitations, competition from other genetic testing providers and the general reluctance around genetic testing. The ROI on such marketing investments in the diagnostic sector historically shows modest returns.
This partnership, while well-intentioned, doesn't materially impact Myriad's market position or financial outlook. The MyRisk® with RiskScore® test, despite being industry-leading, operates in a highly competitive genetic testing market where similar products are available from companies like Invitae and Color Genomics. Social media awareness campaigns, even with notable personalities, rarely drive significant volume increases in genetic testing services.
The demographic reach through Storm's sports audience may help diversify Myriad's customer base, but the conversion rate from awareness to testing is typically low in this sector. Without pricing details or specific campaign performance metrics, this appears to be a standard marketing initiative rather than a market-moving development.
SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally renowned sports broadcaster, who recently revealed her battle with breast cancer.
Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the MyRisk® with RiskScore® Hereditary Cancer Test, the first and industry-leading hereditary cancer test and polygenic risk prediction test for all ancestries. She will promote the importance of collecting a detailed family health history for cancer and understanding the associated cancer risks.
“Knowing your risk for breast cancer helps you and your provider come up with the game plan for prevention and treatment,” said Storm. “I’m a mother of three daughters, so another very important aspect of genetic testing for me is understanding what I could potentially be passing along to them. This information can help their clinicians determine if they would benefit from early detection tools like ultrasounds and MRIs. For me, additional screening made all the difference in catching my cancer at an early stage.”
“I didn't realize that it was really important to understand what kind of cancers were on both sides of your family. My father died of cancer, but it never occurred to me that because he had cancer that I might have an elevated risk of having cancer,” she continued.
Storm is a longtime SportsCenter anchor and NBC sports anchor, and host of the podcast “NBA DNA with Hannah Storm.” Her world changed in January 2024, when she was diagnosed with stage zero Ductal Carcinoma in Situ (DCIS). A routine mammogram detected something suspicious, prompting an ultrasound, which led to a biopsy that revealed DCIS.
“We commend Hannah for raising awareness about the importance of knowing one’s family health history, as a survey suggests nearly half of women may not know their family health history1,” said Paul J. Diaz, President and CEO, Myriad Genetics. “Working with someone of Hannah’s caliber and reach can encourage more women to engage in conversations about their family’s health history and consider potential preventive steps in consultation with their healthcare providers.”
Storm will share content about the importance of knowing family health history on her social media platforms. She plans to share a number of posts about how to have conversations with your family about hereditary cancers, the importance of knowing both sides of your family health history and what questions to ask.
About MyRisk® Hereditary Cancer Test with RiskScore®
MyRisk with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment individualized to them.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s belief that working with someone of Hannah’s caliber and reach can encourage more women to engage in conversations about their family’s health history and consider potential preventive steps in consultation with their healthcare providers. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
1 2022 Myriad Genetics Health Survey.
FAQ
What is the purpose of Myriad Genetics' (MYGN) partnership with Hannah Storm?
When was Hannah Storm diagnosed with breast cancer and what type?
What percentage of women don't know their family health history according to Myriad Genetics (MYGN)?
What specific product is Hannah Storm promoting for Myriad Genetics (MYGN)?
